ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: PO1131

Use of Cytokine Adsorbing Membranes in Patients with Acute Renal Failure in Intensive Care Units

Session Information

Category: Dialysis

  • 701 Dialysis: Hemodialysis and Frequent Dialysis

Authors

  • Jakopin, Eva, Univerzitetni Klinicni Center Maribor, Maribor, Maribor, Slovenia
  • Hren, Martin, Univerzitetni Klinicni Center Maribor, Maribor, Maribor, Slovenia
  • Stropnik Galuf, Tina, Univerzitetni Klinicni Center Maribor, Maribor, Maribor, Slovenia
  • Knehtl, Masa, Univerzitetni Klinicni Center Maribor, Maribor, Maribor, Slovenia
  • Zorman, Tadej, Univerzitetni Klinicni Center Maribor, Maribor, Maribor, Slovenia
  • Vodošek Hojs, Nina, Univerzitetni Klinicni Center Maribor, Maribor, Maribor, Slovenia
  • Ekart, Robert, Univerzitetni Klinicni Center Maribor, Maribor, Maribor, Slovenia
  • Hojs, Radovan, Univerzitetni Klinicni Center Maribor, Maribor, Maribor, Slovenia
  • Bevc, Sebastjan, Univerzitetni Klinicni Center Maribor, Maribor, Maribor, Slovenia
Background

Use of cytokine adsorbents has been proposed as a novel therapeutic approach in sepsis management. Our aim was to evaluate laboratory markers, clinical parameters and SOFA (Sequential Organ Failure Assessment) score in patients who were treated with cytokine adsorbing membrane (CytoSorb®, CytoSorbents Corp. New Jersey, USA) and continuous veno-venous haemodialysis.

Methods

We included adult patients with septic shock and acute renal failure. We retrospectively collected laboratory results (leukocytes, thrombocytes, C-reactive protein, procalcitonin, lactate, urea, creatinine, bilirubin, PaO2), clinical parameters (mean arterial pressure (MAP), FiO2, residual diuresis), SOFA score and vasopressor use at the beginning and at the end of the procedure.

Results


We included 69 patients, 51 men, aged 56.6 ± 15 years. 51 patients had 1 procedure, 14 patients had 2 procedures, 3 patients had 3 procedures and 1 patient had 4 procedures. Median time from admission to initiation of procedure was 47 hours, median treatment time was 23.6 hours.
We discovered significant improvement in procalcitonin (35.36 ± 37.33 ng/mL vs. 24.25 ± 31.18 ng/mL; p<0.001), creatinine (345.06 ± 174.65 μmol/L vs. 233.11 ± 108.82 μmol/L; p<0.0001), SOFA score (14.20 ± 2.64 vs. 12.69 ± 3.52; p<0.001) and FiO2 (48.17 ± 21.17 % vs. 44.63 ± 21.45 %; p=0.020).
Patients with more than 1 procedure showed statistically significant reduction in lactate level (5.40 ± 4.74 mmol/L vs. 2.46 ± 1.74 mmol/L; p=0.010) and vasopressin dose (1.26 ± 1.61 vs. 0.88 ± 3.2 IU/h; p=0.022).

Conclusion

We observed potential beneficial effect of adsorptive membrane use in septic patients. According to our results two or more procedures were associated with improved laboratory markers and lower vasopressor requirement.